These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7693261)

  • 21. Genetic engineering and coagulation factors.
    Fass DN; Toole JJ
    Clin Haematol; 1985 Jun; 14(2):547-70. PubMed ID: 3930118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig.
    Dickneite G; Nicolay U; Friesen HJ; Reers M
    Thromb Haemost; 1998 Jul; 80(1):192-8. PubMed ID: 9684809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.
    Turecek PL; Gritsch H; Richter G; Auer W; Pichler L; Schwarz HP
    Thromb Haemost; 1997 Mar; 77(3):591-9. PubMed ID: 9066015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others.
    Kim HW; Greenburg AG
    Artif Cells Blood Substit Immobil Biotechnol; 2006; 34(6):537-50. PubMed ID: 17090427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma-derived biological medicines used to promote haemostasis.
    Ofosu FA; Freedman J; Semple JW
    Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of futility of administration of recombinant factor VIIa in trauma.
    Stein DM; Dutton RP; O'Connor J; Alexander M; Scalea TM
    J Trauma; 2005 Sep; 59(3):609-15. PubMed ID: 16361902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hereditary hemorrhagic disorders.
    Batlle J; Scandella D; Savidge G
    Rev Invest Clin; 1994 Apr; Suppl():134-43. PubMed ID: 7886297
    [No Abstract]   [Full Text] [Related]  

  • 30. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of recombinant coagulation proteins.
    Vehar GA
    Ann N Y Acad Sci; 1987; 509():82-8. PubMed ID: 3122622
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of single factor deficiencies: a case study approach.
    Marques MB
    Clin Lab Sci; 2003; 16(2):120-2. PubMed ID: 12757193
    [No Abstract]   [Full Text] [Related]  

  • 33. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
    Friederich PW; Wever PC; Briët E; Doorenbos CJ; Levi M
    Am J Hematol; 2001 Apr; 66(4):292-4. PubMed ID: 11279642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant factor VIIa: a universal hemostatic agent?
    Lloyd JV; Joist JH
    Curr Hematol Rep; 2002 Sep; 1(1):19-26. PubMed ID: 12901121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant plasma proteins.
    Burnouf T
    Vox Sang; 2011 Jan; 100(1):68-83. PubMed ID: 21175657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor VIIa gets even bigger.
    Sheffield WP; Clarke BJ
    Thromb Haemost; 2008 Apr; 99(4):653-4. PubMed ID: 18392320
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma fractionation in blood transfusion service.
    Haskó F; Salamon M; Bartha K; Dobó P
    Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biology of proteins involved in blood coagulation.
    Langner KD; Bröker M; Zettlmeissl G
    Behring Inst Mitt; 1990 Oct; (86):146-69. PubMed ID: 2252460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood transfusion: merits of component therapy. II. The clinical use of plasma and plasma components.
    Buchholz DH
    J Pediatr; 1974 Feb; 84(2):165-72. PubMed ID: 4589841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.